Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, CMU, Rue Michel-Servet 1, 1211 Genève 4, Switzerland; Laboratory of Microsystems 4, STI-IMT, Station 17, EPFL, 1015 Lausanne, Switzerland.
Laboratory of Microsystems 4, STI-IMT, Station 17, EPFL, 1015 Lausanne, Switzerland.
Acta Biomater. 2018 Aug;76:71-79. doi: 10.1016/j.actbio.2018.05.056. Epub 2018 Jun 5.
We present a 3D-printing technology allowing free-form fabrication of centimetre-scale injectable structures for minimally invasive delivery. They result from the combination of 3D printing onto a cryogenic substrate and optimisation of carboxymethylcellulose-based cryogel inks. The resulting highly porous and elastic cryogels are biocompatible, and allow for protection of cell viability during compression for injection. Implanted into the murine subcutaneous space, they are colonized with a loose fibrovascular tissue with minimal signs of inflammation and remain encapsulation-free at three months. Finally, we vary local pore size through control of the substrate temperature during cryogenic printing. This enables control over local cell seeding density in vitro and over vascularization density in cell-free scaffolds in vivo. In sum, we address the need for 3D-bioprinting of large, yet injectable and highly biocompatible scaffolds and show modulation of the local response through control over local pore size.
This work combines the power of 3D additive manufacturing with clinically advantageous minimally invasive delivery. We obtain porous, highly compressible and mechanically rugged structures by optimizing a cryogenic 3D printing process. Only a basic commercial 3D printer and elementary control over reaction rate and freezing are required. The porous hydrogels obtained are capable of withstanding delivery through capillaries up to 50 times smaller than their largest linear dimension, an as yet unprecedented compression ratio. Cells seeded onto the hydrogels are protected during compression. The hydrogel structures further exhibit excellent biocompatibility 3 months after subcutaneous injection into mice. We finally demonstrate that local modulation of pore size grants control over vascularization density in vivo. This provides proof-of-principle that meaningful biological information can be encoded during the 3D printing process, deploying its effect after minimally invasive implantation.
我们提出了一种 3D 打印技术,可用于自由成型厘米级可注射结构,实现微创输送。它们是通过在低温基底上进行 3D 打印和优化基于羧甲基纤维素的低温凝胶墨水相结合而产生的。由此产生的高度多孔和弹性低温凝胶具有生物相容性,并允许在注射时压缩过程中保护细胞活力。将其植入小鼠皮下空间后,它们会被疏松的纤维血管组织所定植,炎症迹象很少,并且在三个月内仍然没有被包裹。最后,我们通过在低温打印过程中控制基底温度来改变局部孔径。这使得可以在体外控制局部细胞接种密度,并且可以在无细胞支架中控制血管化密度。总之,我们解决了对大型可注射且高度生物相容的支架进行 3D 生物打印的需求,并通过控制局部孔径来调节局部反应。
这项工作将 3D 增材制造的强大功能与临床优势的微创输送相结合。我们通过优化低温 3D 打印工艺获得了多孔、高可压缩和机械坚固的结构。仅需要基本的商业 3D 打印机和对反应速率和冷冻的基本控制。获得的多孔水凝胶能够承受比其最大线性尺寸小 50 倍的毛细血管输送,这是前所未有的压缩比。在压缩过程中,接种到水凝胶上的细胞得到保护。水凝胶结构在皮下注射到小鼠 3 个月后仍表现出优异的生物相容性。我们最后证明,局部孔径的调节可以控制体内的血管化密度。这证明了在 3D 打印过程中可以编码有意义的生物学信息,并在微创植入后发挥其作用。